Biotech IPO market outperforms AI listings
Analysis based on 7 articles · First reported Jul 21, 2026 · Last updated Jul 21, 2026
Biotech IPOs are attracting significant capital, outperforming AI listings and boosting the sector's valuations. The strong returns and steady pipeline of IPOs suggest continued investor appetite, potentially driving further gains in biotech stocks and related indices.
The biotechnology sector is outperforming AI-related listings in the US IPO market, with biotech and pharmaceutical IPOs delivering a weighted average return of 55% in 2026, compared to a 4.4% weighted average loss for the broader US IPO market. At least six biotechs, led by Scribe Therapeutics Inc., have filed for IPOs in July. Drivers include a 13% gain in the Sana Biotechnology, stable regulatory backdrop, trial data breakthroughs, and acquisitions by big pharma. Notable buyouts include AbbVie's purchase of Apogee Therapeutics, GSK Plc's deal for Nuvalent Inc., and Vertex Pharmaceuticals's purchase of Crinetics Pharmaceuticals Proceeds from biotech IPOs have topped $5 billion, including Parabilis Medicines's $770.6 million offering. Veradermics Inc. is up over 500% since its February debut, and Hemab Therapeutics Holdings Inc. has more than doubled since its May IPO. Concerns remain about higher-for-longer interest rates, but the sector is currently trading independently of that.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard